Neurocrine's Valbenazine study failed its primary endpoint for schizophrenia, while CRENESSITY and INGREZZA reported mixed sales results.
2 reports, 2 independent
Updated Jul 31
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Neurocrine's Valbenazine study failed its primary endpoint for schizophrenia, while CRENESSITY and INGREZZA reported mixed sales results.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Neurocrine Biosciences
American biopharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- GuruFocus.comNeurocrine Biosciences Inc (NBIX) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... Net Product Sales: $682 million in Q2 2025, representing 17% year-over-year growth. CRENESSITY Sales: G
- PR NewswireNeurocrine Biosciences Reports Second Quarter 2025 Financial Results Achieved Total Net Product Sales of $682 Million Representing 17% Year-Over-Year Growth INGREZZA® (valbenazine) Second-Quarter 202